Effector Therapeutics Raises $45M to Prove New Concept in Cancer

Published May 24, 2013

Effector Therapeutics Raises M to Prove New Concept in Cancer

Filed under: drug treatment programs in san diego

After Switzerland's Roche paid $ 230 million in cash to buy San Diego's Anadys Pharmaceuticals in 2011, Anadys CEO Steve Worland says he felt like an entrepreneur-in-residence, but without a venture capital firm to call home. So he began to roam the …
Read more on Xconomy

Venture-Backed Ambit Biosciences Prices IPO

Filed under: drug treatment programs in san diego

San Diego-based Ambit Biosciences Corp., which discovers, develops and commercializes drugs to treat needs in oncology, autoimmune and inflammatory diseases, has priced its initial public offering at US$ 8.00 per share. Listing on NASDAQ … In addition …
Read more on Thomson Reuters’ peHUB (press release)